natgillin/translations-raw huggingface dataset:
Because the number of patients with transthyretin amyloidosis is low, the disease is considered ‘rare', and Vyndaqel was designated an ‘orphan medicine' (a medicine used in rare diseases) on 28 August 
Budući da je broj bolesnika s transtiretinskom amiloidozom nizak, bolest se smatra „rijetkom” te se od 28. kolovoza 2006.
What is Vyndaqel? 
Što je Vyndaqel?
Vyndaqel was compared with placebo (a dummy treatment) in 128 patients with transthyretin amyloidosis. 
Lijek Vyndaqel uspoređen je u 128 bolesnika s transtiretinskom amiloidozom s placebom (slijepo liječenje).
What is Vyndaqel used for? 
Za što se Vyndaqel koristi?
For the full list of all side effects and restrictions with Vyndaqel, see the package leaflet. 
Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Vyndaqel potražite u uputi o lijeku.
What benefit has Vyndaqel shown during the studies? 
Koje su koristi lijeka Vyndaqel utvrđene u ispitivanjima?
How has Vyndaqel been studied? 
Kako je Vyndaqel ispitivan?
How does Vyndaqel work? 
Kako djeluje Vyndaqel?
How is Vyndaqel used? 
Kako se Vyndaqel koristi?
24 mg / 1.2 ml 
Bočica (staklo) 24 mg/1,2 ml
20 mg/ml Solution for injection 
20 mg/ml
2 As lower confidence limit (p = 0.95) 
2 kao donja granica pouzdanosti (p = 0,95)
1 Infectious Units 
1 infektivnih jedinica
_*_One 2-ml dose contains: rotavirus serotype* G1 
_*_Jedna doza (2 ml) sadrži: rotavirus serotipa* G1
not less than 2.3 x 106 IU1, 2 * human-bovine rotavirus reassortants (live), produced in Vero cells. 
ne manje od 2,0 x 106 IU1, 2 rotavirus serotipa* P1A[8] ne manje od 2,3 x 106 IU1, 2 * reasortanti humano-bovinih rotavirusa (živi), proizvedeni na Vero stanicama.
Packaging 
Farmaceutski oblik
Oral use sachet (LDPE/Alu/LDPE/paper) 
Peroralna primjena vrećica (LDPE/alu/LDPE/papir)
Immediate Packaging Content 
Put primjene Unutarnje pakiranje Sadržaj
1 sachet 
1 vrećica
MA (EU) number (Invented) name Strength Pharmaceutical Form 
Jačina Farmaceutski oblik
Granules for oral suspension 
60 mg Granule za oralnu otopinu
2years. 
2 godine.
(Risk in bold is statistically significant at the 95% level.) 
(Rizik koji je podebljano otisnut statistički je značajan na razini od 95%.)
Before using your Airexar Spiromax for the first time, you need to prepare it for use as follows: 
Prije nego što ćete prvi put uporabiti Airexar Spiromax, trebate ga pripremiti za uporabu na sljedeći način:
Administration of Airexar Spiromax to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus. 
Primjenu Airexar Spiromaxa u trudnica treba razmotriti samo ako je očekivana korist za majku veća od svakog mogućeg rizika za fetus.
• Airexar Spiromax may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time. 
• Airexar Spiromax može utjecati na normalno stvaranje steroidnih hormona u tijelu, osobito ako ste uzimali visoke doze tijekom duljih razdoblja.
Frequencies are defined as: very common (≥1/10), common (1/100 to 1/10), uncommon (1/1000 to 1/100), rare (1/10,000 to <1/1000) and not known (frequency cannot be estimated from the available data). 
Učestalosti su definirane na sljedeći način: vrlo često (≥1/10), često (1/100 i 1/10), manje često (1/1000 i 1/100), rijetko (1/10 000 i <1/1000) i nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
The safety and efficacy of Airexar Spiromax in this young population have not been established. 
Sigurnost i djelotvornost Airexar Spiromaxa u ove mlade populacije nisu ustanovljene.
Allergic reactions to Airexar Spiromax are uncommon (they may affect up to 1 in 100 people). 
Alergijske reakcije na Airexar Spiromax su manje česte (mogu se javiti u do 1 na 100 osoba).
If you are not using Airexar Spiromax properly and/or you are not breathing in forcefully enough, this may mean that you are not getting enough of the medicine into your lungs. 
Ako ne koristite Airexar Spiromax na ispravan način i/ili ne udišete dovoljno snažno, to može značiti da ne dobivate dovoljno lijeka u pluća.
• Diabetes mellitus (Airexar Spiromax may increase your blood sugar) 
• šećernu bolest (Airexar Spiromax može povisiti šećer u krvi)
- The other ingredient is lactose monohydrate (see section 2 under ‘Airexar Spiromax contains lactose'). 
- Drugi sastojci su laktoza hidrat (vidjeti dio 2 pod „Airexar Spiromax sadrži laktozu”).
If you forget to use Airexar Spiromax Do not take a double dose to make up for a forgotten dose. 
Ako ste zaboravili primijeniti Airexar Spiromax Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
If you are using Airexar Spiromax for asthma, your doctor will want to check your symptoms regularly. 
Ako primjenjujete Airexar Spiromax zbog astme, liječnik će htjeti redovito provjeravati Vaše simptome.
The use of Airexar Spiromax follows three simple steps: open, breathe and close which are outlined below. 
Uporaba Airexar Spiromaxa odvija se u tri jednostavna koraka: otvaranje, udisanje i zatvaranje, koja su
Airexar Spiromax may not be suitable to be taken with some other medicines. 
Airexar Spiromax možda neće biti pogodno uzimati s nekim drugim lijekovima.
Talk to your doctor, pharmacist or nurse before using Airexar Spiromax if you have: 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite Airexar Spiromax ako imate:
Salmeterol is a selective long-acting (12 hour) β2 adrenoceptor agonist with a long side chain which binds to the exo-site of the receptor. 
Salmeterol je selektivni dugodjelujući (12 sati) agonist β2 adrenoceptora s dugim postraničnim lancem kojim se veže za egzo-mjesto na receptoru.
What Airexar Spiromax is and what it is used for 
Što je Airexar Spiromax i za što se koristi
This is because using too much Airexar Spiromax may reduce the amount of steroid hormones produced by your adrenal glands. 
To je zato što uzimanje previše Airexar Spiromaxa može smanjiti količinu steroidnih hormona koje stvaraju
Tell your doctor if you notice any of the following symptoms while taking Airexar Spiromax as they could be symptoms of a lung infection: fever or chills; increased mucus production, changes in mucus colour; increased cough or increased breathing difficulties. 
Obavijestite liječnika ako primijetite neki od sljedećih simptoma dok uzimate Airexar Spiromax jer to mogu biti simptomi plućne infekcije: vrućica ili zimice; pojačano stvaranje sluzi, promjena boje sluzi; pojačan kašalj ili pojačane tegobe s disanjem.
Tell your doctor, but do not stop taking Airexar Spiromax unless the doctor tells you to stop. 
Obavijestite liječnika, ali nemojte prestati uzimati Airexar Spiromax osim ako Vam liječnik ne kaže da prestanete.
• Airexar Spiromax should be inhaled through the mouth into the lungs. 
• Airexar Spiromax treba udahnuti u pluća kroz usta.
There were no other differences in safety profile between the treatment arms. 
Nije bilo drugih razlika u sigurnosnom profilu između terapijskih
Each Airexar Spiromax inhaler contains 60 inhalations and has a white body with a semi-transparent yellow 
Jedan Airexar Spiromax inhalator sadrži 60 udaha i ima bijelo tijelo s poluprozirnim žutim poklopcem
If this happens stop using your Airexar Spiromax inhaler. 
Ako se to dogodi, prestanite koristiti svoj Airexar Spiromax inhalator.
It is very important that you take your Airexar Spiromax every day as directed. 
Jako je važno da uzimate Airexar Spiromax svaki dan prema uputama.
Airexar Spiromax is not available on the market at strengths lower than 50/500 microgram. 
Airexar Spiromax nije dostupan na tržištu u dozama manjima od 50/500 mikrograma.
• Use your Airexar Spiromax every day until your doctor advises you to stop. 
• Primjenjujte svoj Airexar Spiromax svaki dan dok Vam liječnik ne kaže da prestanete.
Do not stop or suddenly reduce your dose of Airexar Spiromax. 
Nemojte prestati ili naglo smanjiti dozu Airexar Spiromaxa.
If you have used too many doses of Airexar Spiromax for a long time, you should talk to your doctor or pharmacist for advice. 
Ako ste uzimali previše doza Airexar Spiromaxa tijekom duljeg razdoblja, obratite se liječniku ili ljekarniku za savjet.
• Do not stop taking Airexar Spiromax or reduce the dose of Airexar Spiromax without talking to your doctor first. 
• Nemojte prestati uzimati Airexar Spiromax ili smanjiti dozu Airexar Spiromaxa a da o tome prvo niste razgovarali sa svojim liječnikom.
If you get any of these effects or if they happen suddenly after using Airexar Spiromax, stop using Airexar Spiromax and tell your doctor straight away. 
Ako primijetite neki od ovih učinaka ili ako se iznenada pojave nakon primjene Airexar Spiromaxa, prestanite primjenjivati Airexar Spiromax i odmah obavijestite liječnika.
Two children on salmeterol/fluticasone propionate/ and 5 children on fluticasone propionate withdrew because of worsening asthma. 
Dvoje djece koje je primalo salmeterol/flutikazonpropionat i 5 djece koja su primala flutikazonpropionat povuklo se iz ispitivanja zbog pogoršanja astme.
A decision must be made whether to discontinue breastfeeding or to discontinue Airexar Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. 
Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje/suzdržati se od liječenja lijekom Airexar Spiromax uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
The studies described below (GOAL, TORCH and SMART) were carried out with this same fixed-dose combination, salmeterol xinafoate and fluticasone propionate, but studied a previously authorised product; the studies described were not carried out with Airexar Spiromax. 
Niže opisana ispitivanja (GOAL, TORCH i SMART) provedena su s ovom istom fiksnom kombinacijom salmeterolksinafoata i flutikazonpropionata, ali su ispitivala prethodno odobren lijek; opisana ispitivanja nisu bila provedena s Airexar Spiromaxom.
If Airexar Spiromax therapy has to be withdrawn due to overdose of the β agonist component of the medicinal product, provision of appropriate replacement steroid therapy should be considered. 
Ako se terapija Airexar Spiromaxom mora obustaviti zbog predoziranja komponentom β agonista u ovom lijeku, potrebno je razmotriti davanje odgovarajuće zamjenske steroidne terapije.
There are no data available from clinical trials on overdose with Airexar Spiromax, however data on overdose with both active substances are given below: 
Nema dostupnih podataka iz kliničkih ispitivanja o predoziranju Airexar Spiromaxom; međutim, podaci o predoziranju objema djelatnim tvarima navedeni su niže:
Allergic reactions: you may notice your breathing suddenly gets worse immediately after using Airexar Spiromax. 
Alergijske reakcije: možete opaziti naglo pogoršanje disanja neposredno nakon uzimanja Airexar Spiromaxa.
• Breathing difficulties or wheezing that gets worse straight after taking Airexar Spiromax. 
• tegobe s disanjem ili piskanje pri disanju koje se pogorša neposredno nakon uzimanja Airexar Spiromaxa.
In order to ensure that patients achieve the PIFR needed to deliver the required dose, the patient is required to be trained on the use of the Spiromax device including instruction on the need to inhale forcefully (see 
Kako bi se osiguralo da bolesnici postignu PIFR potreban da se dostavi potrebna doza, bolesnike treba podučiti uporabi inhalatora Spiromax uključujući uputu o potrebi snažnog udaha (vidjeti dio 4.2).
What Airexar Spiromax looks like and contents of the pack Airexar Spiromax is an inhalation powder. 
Kako Airexar Spiromax izgleda i sadržaj pakiranja Airexar Spiromax je prašak inhalata.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Airexar Spiromax. 
Bolesnicima treba savjetovati da nastave s liječenjem, ali da potraže liječnički savjet ako simptomi astme i dalje budu nekontrolirani ili se pogoršaju nakon uvođenja liječenja Airexar Spiromaxom.
In addition, if you suddenly stop taking Airexar Spiromax or reduce your dose of Airexar Spiromax this may (very rarely) cause you to have problems with your adrenal glands (adrenal insufficiency) which sometimes causes side effects. 
Uz to, ako naglo prestanete uzimati Airexar Spiromax ili smanjite dozu Airexar Spiromaxa, to može (vrlo rijetko) prouzročiti probleme s nadbubrežnim žlijezdama (insuficijenciju nadbubrežnih žlijezda), što ponekad
Airexar Spiromax is not intended as the treatment of asthma when a fixed-dose combination of salmeterol and fluticasone propionate is required for the first time. 
Airexar Spiromax nije namijenjen za liječenje astme kada se prvi put pokaže da je potrebna fiksna kombinacija salmeterola i flutikazon propionata.
You must use Airexar Spiromax every day as directed by your doctor. 
Airexar Spiromax morate koristiti svaki dan prema uputama Vašeg liječnika.
This can increase your risk of side effects with Airexar Spiromax, including irregular heartbeats, or may make 
To može povisiti rizik od nuspojava kod primjene Airexar Spiromaxa, uključujući nepravilan rad srca, ili pogoršati
In a study in 158 children aged 6 to 16 years with symptomatic asthma, the combination of salmeterol/ fluticasone propionate/ is as efficacious as doubling the dose of fluticasone propionate in respect of symptom control and lung function. 
U ispitivanju u 158 djece u dobi od 6 do 16 godina sa simptomatskom astmom, kombinacija salmeterola/flutikazonpropionata jednako je učinkovita s obzirom na kontrolu simptoma i plućnu funkciju kao i udvostručenje doze flutikazonpropionata.
Patients may notice a taste when using Airexar Spiromax due to the lactose excipient. 
Bolesnici mogu osjetiti nekakav okus nakon uporabe Airexar Spiromaxa, zbog pomoćne tvari laktoze.
Airexar Spiromax contains two medicines, salmeterol and fluticasone propionate: 
Airexar Spiromax sadrži dva lijeka, salmeterol i flutikazonpropionat:
Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. 
Airexar Spiromax je indiciran za simptomatsko liječenje bolesnika s KOPB-om, s FEV1 <60% predviđene normale (prije primjene bronhodilatatora) i s ponavljajućim egzacerbacijama u anamnezi, koji imaju značajne simptome unatoč redovitoj terapiji bronhodilatatorom.
The study showed that doubling the inhalations of each strength of salmeterol/fluticasone propionate for up to 14 days resulted in a small increase in β agonistrelated adverse events (tremor - 1 patient [1%] vs 0, palpitations - 6 [3%] vs 1 [<1%], muscle cramps -6 [3%] vs 1 [<1%]) and a similar incidence of inhaled corticosteroid related adverse events (e.g. oral candidiasis - 6 [6%] vs 16 [8%], hoarseness - 2 [2%] vs 4 [2%]) compared with one inhalation twice daily. 
Ispitivanje je pokazalo da je udvostručavanje broja inhalacija za svaku pojedinu jačinu salmeterola/flutikazonpropionata tijekom najviše 14 dana rezultiralo malim povećanjem nuspojava povezanih s β-agonistom (tremor - 1 bolesnik [1%] naspram 0, palpitacije - 6 [3%] naspram 1 [<1%], mišićni grčevi - 6 [3%] naspram 1 [<1%]) i sličnom incidencijom nuspojava povezanih s inhalacijskim kortikosteroidom (npr. oralna kandidijaza- 6 [6%] naspram 16 [8%], promuklost- 2 [2%] naspram 4 [2%]) u usporedbi s jednom inhalacijom dvaput dnevno.
In cases of both acute and chronic fluticasone propionate overdose Airexar Spiromax therapy should be continued at a suitable dose for symptom control. 
U slučajevima i akutnog i kroničnog predoziranja flutikazonpropionatom potrebno je nastaviti terapiju Airexar Spiromaxom u prikladnoj dozi za kontrolu simptoma.
Airexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate: 
Airexar Spiromax je indiciran za redovito liječenje bolesnika s teškom astmom kod kojih je primjereno primijeniti kombinirani lijek (inhalacijski kortikosteroid i dugodjelujući β2-agonist):
Airexar Spiromax should be administered with caution in patients with active or quiescent pulmonary tuberculosis and fungal, viral or other infections of the airway. 
Airexar Spiromax treba primjenjivati s oprezom u bolesnika s aktivnom ili latentnom tuberkulozom i gljivičnim, virusnim ili drugim infekcijama dišnih putova.
If your doctor feels that you need a lower dose than is available from your Airexar Spiromax, your doctor may prescribe an alternative inhaler containing the same active substances as your Airexar Spiromax but with a lower dose of the corticosteroid. 
Ako liječnik smatra da trebate nižu dozu od one koja je dostupna iz Airexar Spiromaxa, liječnik Vam može propisati drugi inhalator koji sadrži iste djelatne tvari kao i Airexar Spiromax ali nižu dozu kortikosteroida.
Airexar Spiromax is not indicated for use in children and adolescents under the age of 18 years (see Section 4.2). 
Airexar Spiromax nije indiciran za primjenu u djece i adolescenata mlađih od 18 godina (vidjeti dio 4.2).
As Airexar Spiromax contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the active substance may be expected. 
Budući da Airexar Spiromax sadrži salmeterol i flutikazonpropionat, mogu se očekivati vrste i težine nuspojava povezanih sa svakom od tih djelatnih tvari.
The safety and efficacy of Airexar Spiromax in children and adolescents aged less than 18 years of age has not been established. 
Sigurnost i djelotvornost Airexar Spiromaxa u djece i adolescenata mlađih od 18 godina nije ustanovljena.
Patients should be made aware that Airexar Spiromax must be used daily for optimum benefit, even when asymptomatic. 
Bolesnici trebaju biti svjesni da se za postizanje optimalne koristi Airexar Spiromax mora primjenjivati svaki dan, čak i kad nema simptoma.
Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen whilst using 
Bolesnicima crnačkog afričkog ili afrokaripskog podrijetla stoga treba savjetovati da nastave s liječenjem, ali da potraže liječnički savjet ako simptomi astme ostanu nekontrolirani ili se pogoršaju dok primjenjuju Airexar Spiromax.
Patients should not be initiated on Airexar Spiromax during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. 
Bolesnicima se ne smije započeti liječenje Airexar Spiromaxom tijekom egzacerbacije ili ako imaju značajno ili akutno pogoršanje astme.
Airexar Spiromax has no or negligible influence on the ability to drive and use machines. 
Airexar Spiromax ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Rarely, Airexar Spiromax may cause cardiac arrhythmias e.g. supraventricular tachycardia, extrasystoles and atrial fibrillation, and a mild transient reduction in serum potassium at high therapeutic doses. 
U rijetkim slučajevima, Airexar Spiromax može prouzročiti srčane aritmije, npr. supraventrikularnu tahikardiju, ekstrasistole i atrijsku fibrilaciju te blago, prolazno sniženje kalija u serumu pri visokim terapijskim dozama.
Keep the mouthpiece closed all the times unless you are about to use your inhaler. 
Poklopac nastavka za usta uvijek držite zatvorenim osim kad se spremate uporabiti inhalator.
The Salmeterol Multi-center Asthma Research Trial (SMART) SMART was a multi-centre, randomised, double blind, placebo-controlled, parallel group 28-week study in the US which randomised 13,176 patients to salmeterol (50 micrograms twice daily) and 13,179 patients to placebo in addition to the patients' usual asthma therapy. 
SMART je bilo multicentrično, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje na usporednim skupinama u trajanju od 28 tjedana u Sjedinjenim Američkim Državama u kojem je randomizirano 13 176 bolesnika na salmeterol (50 mikrograma dvaput dnevno) i 13 179 bolesnika na placebo uz uobičajenu terapiju astme koju su bolesnici uzimali.
Airexar Spiromax should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. 
Potrebno je odmah prekinuti primjenu Airexar Spiromaxa, pregledati bolesnika i, po potrebi, uvesti zamjensku terapiju.
In patients with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed. 
U bolesnika s astmom ili KOPB-om opažen je niži stupanj sistemske izloženosti udahnutom flutikazonpropionatu.
When to start using a new Airexar Spiromax 
Kada početi koristiti novi Airexar Spiromax
Treatment with Airexar Spiromax should not be stopped abruptly in patients with asthma due to risk of exacerbation. 
Liječenje Airexar Spiromaxom ne smije se naglo prekinuti u bolesnika s astmom zbog rizika od egzacerbacije.
However, Airexar Spiromax should not be used to relieve an attack of breathlessness or wheezing. 
Međutim, Airexar Spiromax se ne smije koristiti za ublažavanje samog napadaja nedostatka zraka ili piskanja pri disanju.
The studies described were carried out with a previously authorised product available in three different strengths; the studies were not carried out with 
Opisana ispitivanja bila su provedena s prethodno odobrenim lijekom koji je dostupan u tri različite doze; ta ispitivanja nisu bila provedena s Airexar Spiromaxom.
Fluticasone propionate: 
Flutikazonpropionat
Airexar Spiromax is not likely to affect your ability to drive or use machines. 
Nije vjerojatno da će Airexar Spiromax utjecati na Vašu sposobnost upravljanja vozilima ili rada sa
Airexar Spiromax should be used with caution in patients with severe cardiovascular disorders or heart rhythm abnormalities and in patients with diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or patients predisposed to low levels of serum potassium. 
Airexar Spiromax treba primjenjivati s oprezom u bolesnika s teškim kardiovaskularnim poremećajima i poremećajima srčanog ritma te u bolesnika sa šećernom bolešću, tireotoksikozom, nekorigiranom hipokalijemijom ili u bolesnika sklonih niskim razinama kalija u serumu.
There are no data available on the use of Airexar Spiromax in patients with hepatic impairment. 
Nema dostupnih podataka o primjeni Airexar Spiromaxa u bolesnika s oštećenjem funkcije jetre.
If a patient with severe COPD has experienced pneumonia, treatment with Airexar Spiromax should be re-evaluated. 
Ako bolesnik s teškim KOPB-om dobije pneumoniju, potrebno je ponovno procijeniti liječenje Airexar Spiromaxom.
If you stop using Airexar Spiromax 
Ako prestanete primjenjivati Airexar Spiromax
For patients with COPD experiencing exacerbations, treatment with systemic corticosteroids is typically indicated, therefore patients should be instructed to seek medical attention if symptoms deteriorate with 
Bolesnicima s KOPB-om koji imaju egzacerbacije obično je indicirano liječenje sistemskim kortikosteroidima; stoga bolesnicima treba savjetovati da potraže liječničku pomoć ako im se simptomi pogoršavaju uz Airexar Spiromax.
Airexar Spiromax helps to stop breathlessness and wheeziness coming on. 
Airexar Spiromax pomaže u sprječavanju pojave nedostatka zraka i piskanja pri disanju.
If you feel more wheezy, your chest feels tight more often or you need to use more of your fast-acting ‘reliever' medicine, your chest condition may be getting worse and you could become seriously ill. You should continue to take Airexar Spiromax but do not increase the number of puffs you take. 
Ako osjećate da je piskanje pri disanju jače, ako češće imate osjećaj stezanja u prsištu ili više koristite brzodjelujući lijek za ublažavanje simptoma, stanje Vaših pluća možda se pogoršava i mogli biste se ozbiljno razboljeti.
Airexar Spiromax is not recommended for use in children and adolescents aged less than 18 years. 
Airexar Spiromax se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.